Rx label changes affect OTC use?
This article was originally published in The Tan Sheet
FDA's proposal to update the format of the pregnancy and lactation sections of drug labeling may encourage women to use "safe and effective products," including Rx drugs that "they might otherwise avoid" because of safety concerns, the agency says. The rule published in the May 29 Federal Register would require labels to include "up-to-date information on the risks and benefits of prescription drugs" on pregnant women, their fetuses and lactation. FDA cites studies that found pregnant women often take OTC drugs and dietary supplements instead of prescription products because they perceive those products are safer, even though safety information on OTC products and supplements "is as limited, if available at all, as that for prescription drugs"...
You may also be interested in...
FDA inserts pre-emption language into seven finalized proposed rules, the American Association for Justice reports in a list of the pending rules. In a report critical of the Bush administration's inclusion of such language in agency-wide regulations, AAJ says pre-emption provides a "get out of jail free" card to companies. FDA first mandated pre-emption in the 2006 physician labeling rule. Similar language is in proposed rules on pregnancy and lactation labeling, skin bleaching drug products, OTC drug labeling, OTC analgesics, labeling on calcium claims, sunscreen labels and a proposed fatty acid rule (1"The Tan Sheet" June 9, 2008, In Brief). FDA proposed three of the rules in 2006 and three in 2007. They go into effect 60 days before President Bush leaves office
If J&J’s gamble on a single dose pays off, it could rapidly advance the fight against SARS-CoV2 – but a second study will provide a safety net.
Agency has been prepping Woodcock for the temporary task but what will happen to her role on Operation Warp Speed remains unclear. The move should give Biden team cushion to confirm a permanent leader of whom a top contender is former senior FDA staffer Joshua Sharfstein, a proponent of drug reforms that may irk manufacturers.